Navigation Links
Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis
Date:7/17/2014

THOUSAND OAKS, Calif., July 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. The primary endpoint was the proportion of patients with > 30 percent reduction from baseline in parathyroid hormone (PTH) levels during an Efficacy Assessment Phase (EAP) defined as the period between weeks 20 and 27. Amgen obtained AMG 416 as part of the acquisition of KAI Pharmaceuticals, Inc. in July 2012 and these are the first results to be reported from the Phase 3 program.

In the AMG 416 group, 75.3 percent of patients achieved a > 30 percent reduction from baseline in PTH compared with 9.6 percent in the placebo arm, a statistically significant result. Secondary endpoints included the percent change from baseline during the EAP in serum phosphorus (P) concentration (mean changes of -9.63 and -1.60 percent among patients in the AMG 416 and placebo arms, respectively) and corrected calcium (cCa) concentration (mean changes of -6.69 and 0.58 percent among patients in the AMG 416 and placebo arms, respectively). Both of these secondary endpoint results were statistically significant.   

"Secondary hyperparathyroidism can be a challenging disease to manage and control. There is an important role for an effective calcimimetic that can be administered intravenously with hemodialysis to help treat this disease," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We are encouraged by the results of this study and look forward to sharing results from a second placebo-controlled study later this year, and a head-to-head study
'/>"/>

SOURCE Amgen
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease
2. Amgen To Present At The 32nd Annual J.P. Morgan Healthcare Conference
3. Chief Financial Officer Jonathan M. Peacock to Leave Amgen; Company Appoints Michael A. Kelly Acting Chief Financial Officer
4. Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
5. Amgen Announces 2014 First Quarter Dividend
6. Amgen To Present At The Oppenheimer 24th Annual Healthcare Conference
7. Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
8. Amgens Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94
9. Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
10. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
11. Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgens Acquisition of Onyx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... and ORLANDO, Fla. , ... supporting Inspire therapy continues to grow, with the publication ... published on-line in Otolaryngology – Head and ... causes a worsening of both objective and subjective measures ... directly attribute Inspire therapy for the reduction in obstructive ...
(Date:9/19/2014)... -- Intarcia Therapeutics, Inc. today announced the ... candidate ITCA 650 (continuous subcutaneous delivery of exenatide) in ... at the 50 th Annual Meeting of the ... from the open-label, phase 3 FREEDOM-HBL (high baseline) trial ... with poorly controlled type 2 diabetes. The results were ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
(Date:9/20/2014)... Mexico (PRWEB) September 20, 2014 The ... including Villa del Palmar Cabo San Lucas, Villa La ... relation to Hurricane Odile, with plans to welcome guests ... , As of Sept. 19, all members and guests ... home, thanks to a coordinated effort with government authorities. ...
(Date:9/20/2014)... 2014 Ticket Down is a ... This popular ticket exchange is offering their customer appreciation ... nearing that next step in the entertainment business. The 21-year-old ... the music and entertainment business, but is closing in on ... No. 1 album, will hit the road next year on ...
(Date:9/20/2014)... Lifeinsurancequoteterm.net has released a new blog post explaining the ... provides for vulnerable family members. , Providing financial ... priority for every provider. It is now possible to ... visiting a doctor. , Life insurance plans that ... to $300,000, but only to healthy applicants. Clients who ...
(Date:9/20/2014)... New York, NY (PRWEB) September 20, 2014 ... Ariana Grande concert tickets for her 2015 “Honeymoon ... appreciation promo code ARIANA-2015 for added savings. , In early ... the biggest stars in the world across North America. Twenty-one-year-old ... the “Honeymoon Tour,” which will take her to 25 cities ...
(Date:9/20/2014)... Recently, Best Cheap Hosting USA ... its new website. The new site provides the ... products for customers. Here, people can find a ... decision. Also, it has recommended some excellent web ... of the great web hosting suppliers, InMotion ( ...
Breaking Medicine News(10 mins):Health News:Villa Group Resorts in Cabo Largely Unharmed, Plan to Re-open Early October 2Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 2Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 3Health News:No Medical Exam Life Insurance Provides Financial Protection for Families 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 3Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2
... less health conscious and may be spending less time daily ... that working full time leads to a sedentary life style ... work full time have less time for leisure, which is ... in front of the computer. These seem to be the ...
... Clopidogrel and aspirin is more effective than only aspirin//., ... four countries of the Europe were given the combination ... the study had had a stroke or transient ischemic ... narrower carotid arteries. The experimental group had microscopic blood ...
... say cholesterol may be actually needed to help insulate the ... that too much of it could end up in // ... up as plaque and can cause heart attacks and strokes. ... blame for the build-up. ACAT2 is one of four enzymes ...
... way the final fetal head position is going to be.//, ... and delivery. This is a form of painkiller that is ... pelvic muscles and nerves get the anesthetic medication. The lady ... longer be in pain. ,A study was conducted ...
... of menopausal symptoms. However if this is used in// conjunction ... be altered. ,Scientists of Yale School of Medicine in ... medication taken by breast cancer patients may alter the way ... not even aware of the fact that their patients may ...
... starts on its immunity system to fight the infection.// ... infections are fought by the human immunity system. A ... of Medicine had identified a molecule that triggers the ... caused by the parasite. ,A parasite called Toxoplasma ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: